Psychedelic drug developers atai Life Sciences and Beckley Psytech are set to merge in a transaction that would value Beckley at around $370M. The combined entity, which would be named atai Beckley, would have a leadership team and Board reflective of both companies. Importantly, the transaction is dependent on the outcome of Beckley’s heavily-anticipated Phase 2b study…
